Bavarian Reperfusion Alternatives Evaluation - BRAVE 4

Description:

The majority of trials have separately assessed antiplatelet and antithrombotic therapy for the treatment of patients undergoing primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI). The current trial sought to study the safety and efficacy of combination therapy of prasugrel + bivalirudin compared with clopidogrel + unfractionated heparin (UFH) in these patients.